Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 20 of the 41 sources its claims cite were checked for support.

Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach

Open access

Published version of a preprint

Abstract

Background: Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical translation. Clinical potency can vary considerably depending on tissue source, donor attributes, but importantly, also culture conditions. Lack of standard procedures hinders inter-study comparability and delays the progression of the field. The aim of this study was A- to assess the impact on MSC characteristics when different laboratories, performed analysis on the same MSC material using harmonised culture conditions and B- to understand source-specific differences. Methods: Three independent institutions performed a head-to-head comparison of human-derived adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions. In each centre, cells from one specific tissue source were isolated and later distributed across the network to assess their biological properties, including cell expansion, immune phenotype, and tri-lineage differentiation (part A). To assess tissue-specific function, angiogenic and immunomodulatory properties and the in vivo biodistribution were compared in one expert lab (part B). Results: By implementing a harmonised manufacturing workflow, we obtained largely reproducible results across three independent laboratories in part A of our study. Unique growth patterns and differentiation potential were observed for each tissue source, with similar trends observed between centres. Immune phenotyping verified expression of typical MSC surface markers and absence of contaminating surface markers. Depending on the established protocols in the different laboratories, quantitative data varied slightly. Functional experiments in part B concluded that conditioned media from BM-MSCs significantly enhanced tubulogenesis and endothelial migration in vitro. In contrast, immunomodulatory studies reported superior immunosuppressive abilities for A-MSCs. Biodistribution studies in healthy mice showed lung entrapment after administration of all three types of MSCs, with a significantly faster clearance of BM-MSCs. Conclusion: These results show the heterogeneous behaviour and regenerative properties of MSCs as a reflection of intrinsic tissue-origin properties while providing evidence that the use of harmonised culture procedures can reduce but do not eliminate inter-lab and operator differences.

Overview

CoChat Summary

TL;DR

This multicentre study harmonised MSC culture across three independent laboratories and found that harmonised procedures improved reproducibility but did not eliminate site-to-site, donor-to-donor, or tissue-origin variability. Tissue source strongly influenced growth, differentiation, angiogenic, immunomodulatory, and in vivo biodistribution behaviour.

Key findings

  • Harmonised culture reduced but did not eliminate inter-lab differences: BM-MSCs consistently showed the longest population doubling times across sites (90.81 ± 10.57 h Heidelberg, 66.78 ± 16.32 h Galway, 95.72 ± 28.02 h Liverpool), compared with A-MSCs (43.17 ± 3.84 h, 37.25 ± 1.64 h, 51.10 ± 1.25 h) and UC-MSCs (68.07 ± 9.11 h, 38.06 ± 1.04 h, 46.06 ± 9.47 h).
  • Differentiation was tissue-dependent and variable: A- and BM-MSCs differentiated into adipocytes and osteocytes, while UC-MSCs showed negligible differentiation, with only one osteogenic outlier in one site.
  • Immunophenotype largely met MSC criteria, with >95% CD73, CD90, and CD105 across sites; however, A-MSCs showed increased negative markers such as CD34 (10.21 ± 12.96% Heidelberg, 18.40 ± 11.69% Liverpool) and CD45 (10.81 ± 7.77% Liverpool), and BM-MSCs showed HLA-DR in Heidelberg and Liverpool (3.70 ± 3.36% and 7.33 ± 6.51%).
  • Functionally, BM-CM enhanced tubulogenesis and endothelial migration, while A-MSCs showed superior immunosuppression: PBMC proliferation was 17 ± 5.2% with A-MSCs, 52 ± 7% with BM-MSCs, and 61 ± 21% with UC-MSCs. All MSC types were entrapped in lungs after IV administration, with faster clearance of BM-MSCs (day 1 normalised signal: 2.5 ± 3.1% BM vs 12.9 ± 3.4% A and 6.3 ± 3.6% UC).

Methods

  • Three independent institutions performed a head-to-head comparison of human adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions: MEM-α, a common FBS lot, and optimised seeding densities (300 cells/cm² for A-MSCs; 3,000 cells/cm² for BM- and UC-MSCs).
  • Part A assessed growth kinetics, tri-lineage differentiation, and immunophenotype across centres after cells were isolated in one centre, cryopreserved, shipped, and expanded in parallel. Part B assessed angiogenic and immunomodulatory properties in expert labs and in vivo biodistribution in healthy C57BL/6 albino female mice using luciferase-expressing MSCs and bioluminescence imaging (n = 4 animals per donor per cell type).
  • Quantitative data are reported as mean ± SD; statistical analyses used GraphPad Prism with p < 0.05 considered significant.

Limitations

  • The paper states that site-to-site variation may be partly due to differing shipment duration on dry ice interrupting the cold chain, and to manual handling of cell counting and confluence assessment; it also states that the effect of international shipping was not evaluated in detail.
  • The paper notes that cryopreservation can affect proliferation, differentiation, and immunosuppressive properties, and that differentiation potential may not be a meaningful selection criterion unless assessed qualitatively or as batch comparisons within one centre.
  • Evident from the text: only three donors per tissue source were used, part B functional assays were each performed in a single expert centre, and the study did not validate the proposed assays in specific injury models to confirm their ability to predict therapeutic potency.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13287-023-03352-1

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic representing study design and assay distribution across centres
Fig. 1 Schematic representing study design and assay distribution across centresCC BY · PubMed Central
Fig. 2 Biological comparison of different tissue sources of MSCs across independent laboratories. a In all sites, A- and UC-MSCs showed enhanced growth kinetics when compared to BM-MSCs, with mean doubling times closer to 40 h for A- and UC-, and 80 to 100 h for BM-MSCs. b Significant differences were observed between sites when comparing the growth rates between sources. c, d A- and BM-MSC were able to undergo different levels of adipogenesis and e, f osteogenesis while UC-MSCs showed a limited ability to differentiate only into osteocytes (one out of 3 donors at one site). g–i Analysis of the immunophenotype by flow cytometry showed adherence to the minimal criteria in all sites, with higher than 95% expression of CD73, CD90 and CD105. Expression of negative markers showed a moderate increase in CD34 (two sites) and CD45 (one site) in A-MSC preparations and a mild increase in HLA-DR in BM-MSC preparations. Data displayed as mean ± SD, N = 3. a One-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.001, ****p < 0.001.
Fig. 2 Biological comparison of different tissue sources of MSCs across independent laboratories. a In all sites, A- and UC-MSCs showed enhanced growth kinetics when compared to BM-MSCs, with mean doubling times closer to 40 h for A- and UC-, and 80 to 100 h for BM-MSCs. b Significant differences were observed between sites when comparing the growth rates between sources. c, d A- and BM-MSC were able to undergo different levels of adipogenesis and e, f osteogenesis while UC-MSCs showed a limited ability to differentiate only into osteocytes (one out of 3 donors at one site). g–i Analysis of the immunophenotype by flow cytometry showed adherence to the minimal criteria in all sites, with higher than 95% expression of CD73, CD90 and CD105. Expression of negative markers showed a moderate increase in CD34 (two sites) and CD45 (one site) in A-MSC preparations and a mild increase in HLA-DR in BM-MSC preparations. Data displayed as mean ± SD, N = 3. a One-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.001, ****p < 0.001.CC BY · PubMed Central
Fig. 3 In vitro angiogenic properties of MSCs. a Representative phase contrast images of tubule-like networks in culture. b–d BM-CM generated significantly more tubular-like structures in a more complex and extended mesh (b), represented by a significantly higher number of junctions (c) and closed loops (d) than its counterparts in a model of in vitro tubulogenesis. Data expressed as a fold-change of the positive control. e Differential angiogenic proteomic profile for each MSC-CM using an antibody array. Data expressed as a fold change of the reference spots. Data displayed as mean ± SD, N = 3, n = 3. Two-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.0001, ****p < 0.00001. #Significance relative to negative control
Fig. 3 In vitro angiogenic properties of MSCs. a Representative phase contrast images of tubule-like networks in culture. b–d BM-CM generated significantly more tubular-like structures in a more complex and extended mesh (b), represented by a significantly higher number of junctions (c) and closed loops (d) than its counterparts in a model of in vitro tubulogenesis. Data expressed as a fold-change of the positive control. e Differential angiogenic proteomic profile for each MSC-CM using an antibody array. Data expressed as a fold change of the reference spots. Data displayed as mean ± SD, N = 3, n = 3. Two-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.0001, ****p < 0.00001. #Significance relative to negative controlCC BY · PubMed Central
Fig. 4 In vitro wound healing properties of MSCs. a BM-CM displayed superior ability to induce endothelial cell migration in an in vitro wound healing model at 8 and 24 h after injury. b Representative phase contrast images at time 24 h after scratch; yellow lines show wound width at time 0 h and white lines at time 8 h after scratch. Increased wound gap can be observed at 24 h in the negative control due to cell death, when HUVECs are grown with serum-free MEM-α. Data displayed as mean ± SD, N = 3, n = 3. Two-way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.0001, ****p < 0.00001. #Significance relative to negative control
Fig. 4 In vitro wound healing properties of MSCs. a BM-CM displayed superior ability to induce endothelial cell migration in an in vitro wound healing model at 8 and 24 h after injury. b Representative phase contrast images at time 24 h after scratch; yellow lines show wound width at time 0 h and white lines at time 8 h after scratch. Increased wound gap can be observed at 24 h in the negative control due to cell death, when HUVECs are grown with serum-free MEM-α. Data displayed as mean ± SD, N = 3, n = 3. Two-way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05, **p < 0.001, **p < 0.0001, ****p < 0.00001. #Significance relative to negative controlCC BY · PubMed Central
Fig. 5 In vitro immunomodulatory capacities of MSCs. a PBMC proliferation after five days co-culture with MSCs under PHA stimulation. All values were normalised to PHA-stimulated monoculture PBMCs. b Mean fluorescence intensity of intracellular IDO of MSCs after being treated with IFN-γ for 24 h. c The percentage of cells positive for IDO intracellular staining. Data are displayed as mean ± SD from N = 3, n = 3. Two-way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05
Fig. 5 In vitro immunomodulatory capacities of MSCs. a PBMC proliferation after five days co-culture with MSCs under PHA stimulation. All values were normalised to PHA-stimulated monoculture PBMCs. b Mean fluorescence intensity of intracellular IDO of MSCs after being treated with IFN-γ for 24 h. c The percentage of cells positive for IDO intracellular staining. Data are displayed as mean ± SD from N = 3, n = 3. Two-way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05CC BY · PubMed Central
Fig. 6 All MSCs were entrapped in the lungs and were short-lived following IV administration. a Representative bioluminescence images of mice administered with FLuc expressing A-, BM- and UC‑MSCs on the day of administration of the cells (day 0), and after 1, 3 and 7 days (radiance scale from 0.2 × 105 to 1 × 106 p/s/cm2/sr). b Light output (flux) as a function of time (days) from the three different types of MSC. c Signal at day 1, day 3, and day 7 normalised to day 0 signal. Data in charts are displayed as mean ± SD from three donors for each type of MSC (4 animals used per donor). Two-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05
Fig. 6 All MSCs were entrapped in the lungs and were short-lived following IV administration. a Representative bioluminescence images of mice administered with FLuc expressing A-, BM- and UC‑MSCs on the day of administration of the cells (day 0), and after 1, 3 and 7 days (radiance scale from 0.2 × 105 to 1 × 106 p/s/cm2/sr). b Light output (flux) as a function of time (days) from the three different types of MSC. c Signal at day 1, day 3, and day 7 normalised to day 0 signal. Data in charts are displayed as mean ± SD from three donors for each type of MSC (4 animals used per donor). Two-Way ANOVA with Tukey’s multiple comparison corrections, *p < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 0 Not valid · 10 Not checked · 86 Own results and interpretations

52 more claims

Create a free account to see all 111 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 40
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 62 references

Cited by

See all 56

Metadata

Authors
Calcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P., O’Brien, T., Taylor, A., & Bieback, K.
Affiliations
  • Ollscoil na Gaillimhe – University of Galway (IE)
  • Heidelberg University (DE)
  • NHS Blood and Transplant (GB)
  • University of Liverpool (GB)
Corresponding author
Bieback, Karen
Venue
Stem Cell Research & Therapy
Published
2023-05-04
Volume
14
Issue
1
Pages
120-120
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4368617526
Cited by
56
References
62
Citations by year
2026: 15 · 2025: 16 · 2024: 17 · 2023: 8
FWCI
5.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • Research Square (submittedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
Funders
  • H2020 European Research Council (813839)
  • Ruprecht-Karls-Universität Heidelberg
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
mesenchymal stem cells, adipose-derived MSCs, bone marrow-derived MSCs, umbilical cord-derived MSCs, donor variability, trilineage differentiation, immunophenotype, angiogenic activity, immunomodulation, in vivo biodistribution
MeSH terms
Animals, Bone Marrow Cells, Cell Differentiation, Cells, Cultured, Humans, Tissue Distribution, Umbilical Cord, Cell Culture Techniques, Cell Proliferation, Mice, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. https://app.cochat.ai/papers/10.1186/s13287-023-03352-1
The paper
Calcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P., O’Brien, T., Taylor, A., & Bieback, K. (2023). Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-023-03352-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.